Advanced metastatic gastric carcinoma

Indication for Mitomycin

Population group: Suitable for both men and women, only adults (18 years old or older)

Mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of advanced metastatic gastric carcinoma.

For this indication, competent medicine agencies globally authorize below treatments:

5-10 mg/m² once every 1-6 weeks

Route of admnistration

Intravenous

Defined daily dose

5 - 10 mg per m² of body surface area (BSA)

Dosage regimen

From 5 To 10 mg per m² of body surface area (BSA) once every 14 day(s)

Detailed description

In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 5-10 mg/m² of body surface every 1-6 weeks, depending on the therapeutic scheme used.

A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².

In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.

Dosage considerations

Bolus injection.

10-20 mg/m² once every 6-8 weeks

Route of admnistration

Intravenous

Defined daily dose

10 - 20 mg per m² of body surface area (BSA)

Dosage regimen

From 10 To 20 mg per m² of body surface area (BSA) once every 42 day(s)

Detailed description

In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 10-20 mg/m² of body surface every 6-8 weeks, depending on the therapeutic scheme used.

A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².

In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.

Dosage considerations

Bolus injection.

8-12 mg/m² once every 3-4 weeks

Route of admnistration

Intravenous

Defined daily dose

8 - 12 mg per m² of body surface area (BSA)

Dosage regimen

From 8 To 12 mg per m² of body surface area (BSA) once every 28 day(s)

Detailed description

In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 8-12 mg/m² of body surface every 3-4 weeks, depending on the therapeutic scheme used.

A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².

In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.

Dosage considerations

Bolus injection.

Active ingredient

Mitomycin is an antibiotic isolated from Streptomyces caespitosus with anti-neoplastic effect. The mechanism of action is based predominantly on the alkylation of DNA (RNA to a lesser extent) with the corresponding inhibition of DNA synthesis. The degree of DNA damage correlates with the clinical effect and is lower in resistant cells than in sensitive ones.

Read more about Mitomycin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner